tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Gain Therapeutics price target raised to $7 from $5 at Maxim

Maxim raised the firm’s price target on Gain Therapeutics (GANX) to $7 from $5 and keeps a Buy rating on the shares. The firm cites the company announcement of initial data from its Phase 1b study of GT-02287 in Parkinson’s disease patients, which was presented in a poster at the International Congress of Parkinson’s Disease and Movement Disorders. Safety was positive overall, and this pharmacokinetic / safety profile checks the right boxes, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1